• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

May 16, 2008 Approval Letter - Measles, Mumps, and Rubella Virus Vaccine, Live

May 16, 2008

Our STN: BL 101069/5172

Merck & Co., Inc.
Attention: Alison Fisher, Ph.D.
P.O. Box 1000
UG2D-6B
North Wales, PA 19454

Dear Dr. Fisher:

We have approved your request to supplement your biologics license application for Measles, Mumps, and Rubella Virus Vaccine Live, to include epididymitis under Urogenital System in the adverse reactions section of the package insert to reflect reports received during post-marketing surveillance, and to include additional minor editorial changes.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide this labeling as a PDF-format electronic copy.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

/Loris D. McVittie, Ph.D./
Loris D. McVittie, Ph.D.
Acting Division Director
Division of Vaccines and Related Products Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

Attachment: Approved Final Draft Labeling

 

Return to product page